INK Ultra Money Free: BioVaxys insiders bet on the haptenization of cancer and covid
During the last week of October we put the Healthcare sector in the spotlight. On Wednesday, we ventured into the biotech space where BioVaxys (BIOV) insiders are betting big on their firm's novel approach to tackling cancer and COVID-19. Join us as a Canadian Insider or INK Research member as we let the insiders guide us to opportunity this fall.
With countless people suffering from anxiety and depression in the wake of the COVID-19 pandemic, could psychedelic drugs be poised to become a key treatment? Christian Angermayer, founder of Apeiron Investments, Atai Life Sciences, and COMPASS Pathways, lays out his vision for the future of the psychedelics sector, in which once-taboo substances like psilocybin are administered in clinical settings on a global scale. In a discussion with JLS Fund managing partner Jeff Siegel, the billionaire gives an inside look into some of the recent ups and downs experienced by Atai and COMPASS. He also explains his view on why Atai is currently undervalued and hints at some big things to come. Recorded on January 10, 2022.
Aug 12, 2021
Investing in the Future of Mental Health Care: Psychedelics as an Asset Class
Prior to Nixon's War on Drugs in the 70s, tens of millions of dollars were being poured into psychedelic research for treating mental health issues such as schizophrenia—and in recent years, new life has been breathed into psychedelic research for therapeutic treatment that has led to a nascent and investable sector. Jeff Siegel, managing partner at JLS Fund, provides an overview of the psychedelics space and why now is a good time to invest in it. He also shares how the science around psychedelic research is progressing, his future outlook on the sector’s growth, and how psychedelic therapy can fundamentally transform the future of mental health care. Interviewed by Ash Bennington on August 5, 2021.
Where Tech and Medicine Meet Cannabis: Paving the Future of Healthcare
After the devastating Tuscaloosa tornados of 2011, Livi McKay lost everything and was left with debilitating health issues that traditional medicine could not effectively treat—until she started using cannabis. She joins Tony Greer of TG Macro to share her story from growing up in a conservative family in Alabama, where cannabis was highly illegal, to becoming the founder and CEO of MyTEPI in Nevada. She explains how she’s using plant-based pharmacology to equip dispensaries with science-backed knowledge of cannabis’s therapeutic effects for the benefit of end users. McKay also discusses how her vision for the future of healthcare coincides with other ongoing developments in the medical industry such as psychedelic therapy and DNA sequencing. Filmed on September 27, 2021.
Transforming the Treatment of Mental Health with Psychedelic Medicine
We’re in a psychedelic renaissance. Rather than using Selective Serotonin Reuptake Inhibitors (SSRIs) to manage symptoms, a new approach at Field Trip Health is trying to get to the root causes of mental health conditions. Field Trip Health co-founder and chief clinical officer Ryan Yermus and Field Trip Health VP of healthcare practice Matt Emmer are working together to use psychedelic medicine, like ketamine, and trained therapists as an alternative to SSRIs in treating mental health conditions in order to transform this field of medicine. Their innovative approach to mental health treatment is also reflected in their development of novel molecule FT-104, which offers the promise of a shorter, guided psychedelic trip, allowing for the experience to be more accommodative for patients, and widens the landscape for business development due to its proprietary nature. Interviewed by Ash Bennington on October 29, 2021.
Mar 21, 2022
How Blockchain Can Make Medicine Better
Clinical trials are a crucial part of the development of new medicines. But existing processes are antiquated, and it can take as many as 10 years before a new drug is approved. As demonstrated during the response to the COVID-19 pandemic, efficient influx of vaccines and other innovative solutions is critical for society’s current and future medical needs. Triall is leading the deployment of blockchain-integrated software solutions to accelerate delivery of new drugs to patients. Triall co-founder and CEO Hadil Es-Sbai and co-founder and head of marketing Raymond van der Waal join Santiago Velez, co-founder and division lead of R&D at Block Digital, to talk about the world’s first digital ecosystem for clinical trials and how it will improve reliability and efficiency in the drug-development process. Recorded on March 7, 2022.